Welcome to our dedicated page for VRAY news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on VRAY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VRAY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VRAY's position in the market.
ViewRay, Inc. (NASDAQ: VRAY) has scheduled a conference call for April 13, 2023, at 8:00 AM ET to discuss preliminary financial results for the first quarter of 2023. Domestic callers can join at (888) 886-7786 using confirmation number 56031524. A live webcast will also be available on ViewRay's investor relations page. The MRIdian® MR-Guided Radiation Therapy System, designed with high-definition MR imaging, addresses challenges in advanced radiation oncology, such as beam distortion and skin toxicity. This innovative technology differentiates itself from conventional MR systems used in diagnostic radiology.
ViewRay (NASDAQ: VRAY) announced that the Czech Ministry of Health has approved the acquisition of its MRIdian system, making it the first and only facility to provide advanced MRI-guided radiation therapy in the Czech Republic at the Military University Hospital Prague. This purchase, partially funded by the REACT-EU financial instrument, enhances cancer treatment options with precision technology that includes real-time tissue tracking and automatic beam control. Over 29,000 patients have already benefited from MRIdian systems, which are installed in 57 hospitals worldwide.
